Substituted 2(2,6-dioxopiperidin-3-yl)isoindolines
US6335349B1 · kind B1 · utility
142Cited by
27References
23Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 20, 2000 |
| Grant date | Jan 1, 2002 |
| Priority date | — |
| Expiry date | Dec 5, 2020 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K47/42
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Substituted 1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindolines and 1-oxo-2-(2,6-dioxo-piperidin-3-yl)isoindolines reduce the levels of TNF&agr; in a mammal and are useful in treating oncogenic conditions, inflammation, and autoimmune diseases. Typical embodiments are 1-oxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4,5,6,7-tetrafluoroiso-indoline and 1,3-dioxo-2-(2,6-dioxo-3-methylpiperidin-3-yl)-4-aminoisoindoline.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.